Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Barzolvolimab (Primary) ; Antihistamines; Leukotriene receptor agonists
Indications Chronic urticaria; Cold Urticaria; Familial dermographism
Focus Adverse reactions
Sponsors Celldex Therapeutics Inc

26 Feb 2024 According to a Celldex Therapeutics Inc media release, in October 2023, data on quality of life outcomes from the Phase 1b CSU study were presented at the European Academy of Dermatology & Venereology (EADV) Congress.
10 Jun 2023 Results presented in a Celldex Therapeutics Inc media release.
10 Jun 2023 According to a Celldex Therapeutics Inc media release, data from this study were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com